Helix BioPharma Corp. | Income Statement
Fiscal year is August-July. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
396.00
232.00
133.00
134.00
130.00
167
Gross Income
396.00
232.00
133.00
134.00
130.00
167
SG&A Expense
8,170.00
8,701.00
8,833.00
9,698.00
10,362.00
8,511
EBIT
8,566.00
8,933.00
8,966.00
9,832.00
10,492.00
8,678
Non Operating Income/Expense
16.00
29.00
59.00
34.00
187.00
88
Interest Expense
-
19.00
-
-
-
-
Pretax Income
8,532.00
8,880.00
8,969.00
9,840.00
10,289.00
8,757
Income Tax
338.00
198.00
189.00
175.00
230.00
132
Consolidated Net Income
8,194.00
8,682.00
8,780.00
9,665.00
10,059.00
8,625
Net Income
8,194.00
8,682.00
8,780.00
9,665.00
10,059.00
8,625
Net Income After Extraordinaries
14,843.00
8,682.00
8,830.00
9,665.00
10,059.00
8,625
Net Income Available to Common
7,564.00
8,682.00
8,780.00
9,665.00
10,059.00
8,625
EPS (Basic)
0.02
0.12
0.11
0.11
0.11
0.09
Basic Shares Outstanding
67,226.30
70,955.10
78,592.40
85,550.90
91,797.60
99,928.70
EPS (Diluted)
0.02
0.12
0.11
0.11
0.11
0.09
Diluted Shares Outstanding
67,226.30
70,955.10
78,592.40
85,550.90
91,797.60
99,928.70
EBITDA
8,170.00
8,701.00
8,833.00
9,698.00
10,362.00
8,511
Non-Operating Interest Income
50.00
43.00
56.00
26.00
16.00
9
About Helix BioPharma
View Profile
